89 Beaumont Avenue
Health Science Research Facility (HSRF) 218
Burlington, VT 05405
United States
- Postdoctoral Associate, University of Vermont College of Medicine, Burlington, Vermont
- PhD, Biological Sciences, Madurai Kamaraj University, Madurai, India
- MSc, Biotechnology, University of Mysore, Mysore, India
- BSc, Biochemistry, Botany and Zoology, University of Mysore, Mysore, India
Department of Pathology and Laboratory Medicine
University of Vermont Cancer Center
Areas of expertise
Endoplasmic Reticulum (ER) stress and Protein Disulfide Isomerases in asthma
Unfolded Protein Response in respiratory virus infection
Redox regulation of inflammatory response and airway remodeling in asthma
Redox based epithelial dysregulation in pulmonary fibrosis and cancer
BIO
The overarching goal of Dr. Anathy’s research is to understand the impact of oxidative post-translational protein modifications (OXPTM) and their functional consequences in lung diseases. We have a strong record of accomplishment in endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), epithelial apoptosis, redox biology, asthma, influenza infection and lung fibrosis. New themes are emerging in our research, focusing on the role of ER stress and ER-based oxidoreductases in influenza infection, pulmonary fibrosis, as well as a novel link to asthma exacerbation. We have developed new strains of mice to achieve lung epithelial-specific deletion of ER-based redox enzymes, mitochondrial fission proteins, and transcription factors critical in developing lung inflammatory response and fibrosis. We have tested ER signaling-based reagents, pharmacological agents, and optimized sensitive enzyme assays in mouse and human samples to investigate the role of ER-based oxidoreductases in airway inflammation and fibrosis associated with asthma and influenza infection or acute lung injury.
Publications
Dr. Anathy's publications on PubMed
Awards and Achievements
2024 US Patent, 11883395; Method of Treating severe acute respiratory syndrome (SARS) infection by administering a protein disulfide isomerase (PDI) inhibitor, Issued May 14, 2020
2018 US Patent, 9,907,828; Treatments of Oxidative Stress Conditions, Issued March 6, 2018
2008 US Patent, 8,679,811 B2, Treatments Involving Glutaredoxins and Similar Agents, European patent P2167653 (A2), Int'l publication number WO 2008/154012 (A2)
Bio
The overarching goal of Dr. Anathy’s research is to understand the impact of oxidative post-translational protein modifications (OXPTM) and their functional consequences in lung diseases. We have a strong record of accomplishment in endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), epithelial apoptosis, redox biology, asthma, influenza infection and lung fibrosis. New themes are emerging in our research, focusing on the role of ER stress and ER-based oxidoreductases in influenza infection, pulmonary fibrosis, as well as a novel link to asthma exacerbation. We have developed new strains of mice to achieve lung epithelial-specific deletion of ER-based redox enzymes, mitochondrial fission proteins, and transcription factors critical in developing lung inflammatory response and fibrosis. We have tested ER signaling-based reagents, pharmacological agents, and optimized sensitive enzyme assays in mouse and human samples to investigate the role of ER-based oxidoreductases in airway inflammation and fibrosis associated with asthma and influenza infection or acute lung injury.
Publications
Awards and Achievements
2024 US Patent, 11883395; Method of Treating severe acute respiratory syndrome (SARS) infection by administering a protein disulfide isomerase (PDI) inhibitor, Issued May 14, 2020
2018 US Patent, 9,907,828; Treatments of Oxidative Stress Conditions, Issued March 6, 2018
2008 US Patent, 8,679,811 B2, Treatments Involving Glutaredoxins and Similar Agents, European patent P2167653 (A2), Int'l publication number WO 2008/154012 (A2)